Literature DB >> 22094243

MRI as a tool for evaluation of oral controlled release dosage forms.

Przemysław P Dorożyński1, Piotr Kulinowski, Anna Młynarczyk, Greg J Stanisz.   

Abstract

The magnetic resonance imaging (MRI) studies of controlled-release (CR) dosage forms can be roughly divided into two groups. The first comprises studies performed in static conditions (small solvent volumes and ambient temperature). Such studies have provided insight into molecular phenomena in hydrating polymeric matrices. The second group covers research performed in dynamic conditions (medium flow or stirring) related to drug dissolution. An important issue is supplementation of the MRI results with data obtained by complementary techniques, such as X-ray microtomography (μCT). As we discuss here, an understanding of the mechanism underlying the release of the drug from the dosage form will lead to the development of detailed, molecularly defined, CR dosage forms.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22094243     DOI: 10.1016/j.drudis.2011.10.026

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  2 in total

1.  Magnetic resonance microscopy for assessment of morphological changes in hydrating hydroxypropylmethyl cellulose matrix tablets in situ.

Authors:  Piotr Kulinowski; Anna Młynarczyk; Przemysław Dorożyński; Krzysztof Jasiński; Marco L H Gruwel; Bogusław Tomanek; Władysław P Węglarz
Journal:  Pharm Res       Date:  2012-08-25       Impact factor: 4.200

2.  Magnetic resonance microscopy for assessment of morphological changes in hydrating hydroxypropylmethylcellulose matrix tablets in situ-is it possible to detect phenomena related to drug dissolution within the hydrated matrices?

Authors:  Piotr Kulinowski; Anna Młynarczyk; Krzysztof Jasiński; Przemysław Talik; Marco L H Gruwel; Bogusław Tomanek; Władysław P Węglarz; Przemysław Dorożyński
Journal:  Pharm Res       Date:  2014-03-15       Impact factor: 4.200

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.